Synektik S.A. stock (PLSYNEK00016): imaging and radiopharmaceutical group reports recent orders and expansion steps

Poland-based medical imaging and radiopharmaceutical specialist Synektik S.A. has reported recent contract wins and expansion steps in its diagnostic imaging and radiopharmaceutical businesses, drawing interest from investors watching European healthcare suppliers.

Polish healthcare technology group Synektik S.A. has highlighted new contracts and expansion initiatives in diagnostic imaging and radiopharmaceuticals in recent months, including orders for advanced imaging equipment and continued development of its radiopharmaceutical production capabilities, according to company updates published on its investor relations website in early 2025 and late 2024Synektik investor materials as of 01/2025Synektik current reports as of 12/2024.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Synektik
• Sector/industry: Medical imaging and radiopharmaceuticals
• Headquarters/country: Poland
• Core markets: Central and Eastern European hospital and diagnostic imaging market
• Key revenue drivers: Diagnostic imaging equipment, radiopharmaceutical sales, service and integration projects
• Home exchange/listing venue: Warsaw Stock Exchange (ticker: SNT)
• Trading currency: Polish zloty (PLN)

Synektik S.A.: core business model

Synektik S.A. focuses on comprehensive solutions for diagnostic imaging and nuclear medicine, combining equipment distribution, integration services and radiopharmaceutical production for hospitals and clinics in Poland and neighboring markets, as outlined in its corporate profile for investors published in 2024Synektik company overview as of 06/2024.

The company positions itself as a supplier of high-end imaging technologies such as PET/CT, SPECT/CT and MRI scanners, often delivered as turnkey projects that include room design, installation and after-sales service. It also develops and supplies radiopharmaceuticals used in oncology and cardiology diagnostics, creating recurring revenue streams tied to examination volumes at customer sitesSynektik company overview as of 06/2024.

Synektik’s integrated approach, which covers equipment, software and consumables, is designed to support hospitals that seek a single partner for major imaging investments. For international investors, the business model provides exposure to healthcare infrastructure spending in Central and Eastern Europe, a region where imaging capacity and cancer diagnostics infrastructure are still catching up with Western European levelsSynektik investor materials as of 01/2025.

Main revenue and product drivers for Synektik S.A.

Synektik’s revenue base is diversified across three main pillars: large medical imaging systems, radiopharmaceuticals and service or integration work. High-value equipment contracts, such as multi-year PET/CT or MRI projects, can drive short-term revenue volatility, while radiopharmaceuticals are typically sold under longer-term supply agreements that align with routine diagnostic imaging volumesSynektik current reports as of 12/2024.

In recent company communications, Synektik has pointed to continued interest from public and private hospitals in expanding PET/CT capacity, supported by oncology programs and reimbursement frameworks in Poland. The company also notes that its contract portfolio includes maintenance and service work, which creates a recurring component that can partially offset the cyclical nature of capital equipment ordersSynektik investor materials as of 01/2025.

The radiopharmaceutical segment benefits as more scanners are deployed across the region, since tracer demand tends to correlate with the number of scans performed. Synektik has invested in production infrastructure and quality systems to supply a portfolio of tracers for oncology and cardiology indications, which can support growth if clinical guidelines or screening programs lead to higher imaging utilizationSynektik company overview as of 06/2024.

Conclusion

Synektik S.A. offers exposure to medical imaging equipment and radiopharmaceutical demand in Central and Eastern Europe, with a focus on nuclear medicine and oncology diagnostics. Recent contract activity and capacity investments, as reflected in its investor communications, suggest ongoing interest from hospitals in expanding imaging capabilities. For US-based investors, the Warsaw-listed stock represents a niche way to track European healthcare infrastructure trends rather than domestic demand. As with all equities, potential investors typically weigh project pipeline visibility, regulatory and reimbursement conditions, and execution risks in capital-intensive healthcare projects before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.